JPMorgan Chase & Co. reiterated their overweight rating on shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $22.00 price objective on the stock.
A number of other research analysts have also recently commented on AMRX. UBS Group upped their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, August 12th. Barclays upped their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $19.00.
Check Out Our Latest Stock Report on AMRX
Amneal Pharmaceuticals Price Performance
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts anticipate that Amneal Pharmaceuticals will post 0.94 earnings per share for the current year.
Insider Activity
In other news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 413,016 shares of company stock valued at $7,216,567. Corporate insiders own 17.30% of the company’s stock.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Several hedge funds have recently made changes to their positions in AMRX. Kemnay Advisory Services Inc. purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $26,000. Public Employees Retirement System of Ohio purchased a new stake in Amneal Pharmaceuticals in the second quarter worth about $29,000. Federated Hermes Inc. lifted its stake in Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares during the period. Comerica Bank grew its holdings in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after acquiring an additional 1,957 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its holdings in Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
